Breast Cancer Research and Treatment

, Volume 127, Issue 1, pp 297–308 | Cite as

Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women

  • Lenora W. M. Loo
  • Yinghui Wang
  • Erin M. Flynn
  • Mary Jo Lund
  • Erin J. Aiello Bowles
  • Diana S. M. Buist
  • Jonathan M. Liff
  • Elaine W. Flagg
  • Ralph J. Coates
  • J. William Eley
  • Li Hsu
  • Peggy L. Porter
Brief Report

Abstract

Genomic copy number alterations (CNA) are common in breast cancer. Identifying characteristic CNAs associated with specific breast cancer subtypes is a critical step in defining potential mechanisms of disease initiation and progression. We used genome-wide array comparative genomic hybridization to identify distinctive CNAs in breast cancer subtypes from 259 young (diagnosed with breast cancer at <55 years) African American (AA) and Caucasian American (CA) women originally enrolled in a larger population-based study. We compared the average frequency of CNAs across the whole genome for each breast tumor subtype and found that estrogen receptor (ER)-negative tumors had a higher average frequency of genome-wide gain (P < 0.0001) and loss (P = 0.02) compared to ER-positive tumors. Triple-negative (TN) tumors had a higher average frequency of genome-wide gain (P < 0.0001) and loss (P = 0.003) than non-TN tumors. No significant difference in CNA frequency was observed between HER2-positive and -negative tumors. We also identified previously unreported recurrent CNAs (frequency >40%) for TN breast tumors at 10q, 11p, 11q, 16q, 20p, and 20q. In addition, we report CNAs that differ in frequency between TN breast tumors of AA and CA women. This is of particular relevance because TN breast cancer is associated with higher mortality and young AA women have higher rates of TN breast tumors compared to CA women. These data support the possibility that higher overall frequency of genomic alteration events as well as specific focal CNAs in TN breast tumors might contribute in part to the poor breast cancer prognosis for young AA women.

Keywords

Breast cancer Triple negative Genomic alteration Array comparative genomic hybridization Young women 

Notes

Acknowledgments

The authors would like to thank Stephanie Stafford for assistance with data management and analysis, the leadership and staff of the FHCRC DNA Array Facility and Jeri Glogovac for flow sorting of tumor samples. The study was supported by funding from NCI RO1 CA64292, P. I. William Eley; NCI R01 CA098415, P. I. Peggy Porter.

Conflict of interest

All authors report no conflict of interest associated with this study.

Supplementary material

10549_2010_1297_MOESM1_ESM.doc (46 kb)
Supplementary material 1 (DOC 46 kb)
10549_2010_1297_MOESM2_ESM.xls (30 kb)
Supplementary material 2 (XLS 30 kb)
10549_2010_1297_MOESM3_ESM.xlsx (48 kb)
Supplementary material 3 (XLSX 48 kb)
10549_2010_1297_MOESM4_ESM.xls (26 kb)
Supplementary material 4 (XLS 25 kb)

References

  1. 1.
    Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492–2502. doi: 295/21/2492[pii]10.1001/jama.295.21.2492 PubMedCrossRefGoogle Scholar
  2. 2.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMedCrossRefGoogle Scholar
  3. 3.
    Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423. doi: 10.1073/pnas.09326921000932692100[pii] PubMedCrossRefGoogle Scholar
  4. 4.
    Yu K, Lee CH, Tan PH, Tan P (2004) Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 10(16):5508–5517. doi: 10.1158/1078-0432.CCR-04-008510/16/5508[pii] PubMedCrossRefGoogle Scholar
  5. 5.
    Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376. doi: 14/5/1368[pii]10.1158/1078-0432.CCR-07-1658 PubMedCrossRefGoogle Scholar
  6. 6.
    Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350. doi: 10.1002/ijc.21004 PubMedCrossRefGoogle Scholar
  7. 7.
    Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661–671. doi: 10.1002/path.1559 PubMedCrossRefGoogle Scholar
  8. 8.
    Diaz LK, Cryns VL, Symmans WF, Sneige N (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14(6):419–430. doi: 10.1097/PAP.0b013e318159473300125480-200711000-00004[pii] PubMedCrossRefGoogle Scholar
  9. 9.
    Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 109(9):1721–1728. doi: 10.1002/cncr.22618 PubMedCrossRefGoogle Scholar
  10. 10.
    Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113(2):357–370. doi: 10.1007/s10549-008-9926-3 PubMedCrossRefGoogle Scholar
  11. 11.
    Lund MJ, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, Green VL, Brawley OW, Oprea-Ilies GM, Gabram SG (2008) High prevalence of triple-negative tumors in an urban cancer center. Cancer 113(3):608–615. doi: 10.1002/cncr.23569 PubMedCrossRefGoogle Scholar
  12. 12.
    Amend K, Hicks D, Ambrosone CB (2006) Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 66(17):8327–8330. doi: 66/17/8327[pii]10.1158/0008-5472.CAN-06-1927 PubMedCrossRefGoogle Scholar
  13. 13.
    Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97(6):439–448PubMedCrossRefGoogle Scholar
  14. 14.
    Dayal HH, Power RN, Chiu C (1982) Race and socio-economic status in survival from breast cancer. J Chronic Dis 35(8):675–683PubMedCrossRefGoogle Scholar
  15. 15.
    Eley JW, Hill HA, Chen VW, Austin DF, Wesley MN, Muss HB, Greenberg RS, Coates RJ, Correa P, Redmond CK et al (1994) Racial differences in survival from breast cancer. Results of the national cancer institute black/white cancer survival study. JAMA 272(12):947–954PubMedCrossRefGoogle Scholar
  16. 16.
    Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA (2006) Meta-analysis of survival in African American and White American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 24(9):1342–1349. doi: 24/9/1342[pii]10.1200/JCO.2005.03.3472 PubMedCrossRefGoogle Scholar
  17. 17.
    Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 97(1):134–147. doi: 10.1002/cncr.11051 PubMedCrossRefGoogle Scholar
  18. 18.
    Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45(11):1033–1040PubMedCrossRefGoogle Scholar
  19. 19.
    Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6):529–541PubMedCrossRefGoogle Scholar
  20. 20.
    Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG (2006) Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6:96PubMedCrossRefGoogle Scholar
  21. 21.
    Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR, Delrow JJ, Trask BJ, Hsu L, Porter PL (2004) Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64(23):8541–8549PubMedCrossRefGoogle Scholar
  22. 22.
    Brinton LA, Potischman NA, Swanson CA, Schoenberg JB, Coates RJ, Gammon MD, Malone KE, Stanford JL, Daling JR (1995) Breastfeeding and breast cancer risk. Cancer Causes Control 6(3):199–208PubMedCrossRefGoogle Scholar
  23. 23.
    Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, Coates RJ, Eley JW (2004) Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 100(12):2533–2542PubMedCrossRefGoogle Scholar
  24. 24.
    Glogovac JK, Porter PL, Banker DE, Rabinovitch PS (1996) Cytokeratin labeling of breast cancer cells extracted from paraffin-embedded tissue for bivariate flow cytometric analysis. Cytometry 24(3):260–267. doi: 10.1002/(SICI)1097-0320(19960701)24:3<260::AID-CYTO9>3.0.CO;2-L Google Scholar
  25. 25.
    Loo LW, Ton C, Wang YW, Grove DI, Bouzek H, Vartanian N, Lin MG, Yuan X, Lawton TL, Daling JR, Malone KE, Li CI, Hsu L, Porter PL (2008) Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer 47(12):1049–1066. doi: 10.1002/gcc.20610 PubMedCrossRefGoogle Scholar
  26. 26.
    Lieb JD, Liu X, Botstein D, Brown PO (2001) Promoter-specific binding of Rap1 revealed by genome-wide maps of protein–DNA association. Nat Genet 28(4):327–334. doi: 10.1038/ng569ng569[pii] PubMedCrossRefGoogle Scholar
  27. 27.
    Yang MC, Ruan QG, Yang JJ, Eckenrode S, Wu S, McIndoe RA, She JX (2001) A statistical method for flagging weak spots improves normalization and ratio estimates in microarrays. Physiol Genomics 7(1):45–53. doi: 7/1/45[pii] PubMedGoogle Scholar
  28. 28.
    Hsu L, Self SG, Grove D, Randolph T, Wang K, Delrow JJ, Loo L, Porter P (2005) Denoising array-based comparative genomic hybridization data using wavelets. Biostatistics 6(2):211–226. doi: 6/2/211[pii]10.1093/biostatistics/kxi004 PubMedCrossRefGoogle Scholar
  29. 29.
    Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20(7):1071–1082. doi: 10.1007/s10552-009-9331-1 PubMedCrossRefGoogle Scholar
  30. 30.
    Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM (2009) Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 116(3):479–489. doi: 10.1007/s10549-008-0117-z PubMedCrossRefGoogle Scholar
  31. 31.
    Wessels LF, van Welsem T, Hart AA, van’t Veer LJ, Reinders MJ, Nederlof PM (2002) Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62(23):7110–7117PubMedGoogle Scholar
  32. 32.
    Adelaide J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P, Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M (2007) Integrated profiling of basal and luminal breast cancers. Cancer Res 67(24):11565–11575. doi: 67/24/11565[pii]10.1158/0008-5472.CAN-07-2536 PubMedCrossRefGoogle Scholar
  33. 33.
    Han W, Jung EM, Cho J, Lee JW, Hwang KT, Yang SJ, Kang JJ, Bae JY, Jeon YK, Park IA, Nicolau M, Jeffrey SS, Noh DY (2008) DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer 47(6):490–499. doi: 10.1002/gcc.20550 PubMedCrossRefGoogle Scholar
  34. 34.
    Bergamaschi A, Kim YH, Kwei KA, La Choi Y, Bocanegra M, Langerod A, Han W, Noh DY, Huntsman DG, Jeffrey SS, Borresen-Dale AL, Pollack JR (2008) CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer. Mol Oncol 2(4):327–339. doi: S1574-7891(08)00124-5[pii]10.1016/j.molonc.2008.09.004 PubMedCrossRefGoogle Scholar
  35. 35.
    Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME et al (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150(3):534–544. doi: 10.1002/jcp.1041500314 PubMedCrossRefGoogle Scholar
  36. 36.
    Deming SL, Nass SJ, Dickson RB, Trock BJ (2000) C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83(12):1688–1695. doi: 10.1054/bjoc.2000.1522S0007092000915222[pii] PubMedCrossRefGoogle Scholar
  37. 37.
    Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M (2006) Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6:245. doi: 1471-2407-6-245[pii]10.1186/1471-2407-6-245 PubMedCrossRefGoogle Scholar
  38. 38.
    Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, Rodriguez-Pinilla SM, Honrado E, Campoverde A, Palacios J, Nathanson KL, Garcia MJ, Benitez J (2009) Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res 11(6):R86. doi: bcr2456[pii]10.1186/bcr2456 PubMedCrossRefGoogle Scholar
  39. 39.
    Abba MC, Fabris VT, Hu Y, Kittrell FS, Cai WW, Donehower LA, Sahin A, Medina D, Aldaz CM (2007) Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res 67(9):4104–4112. doi: 67/9/4104[pii]10.1158/0008-5472.CAN-06-4672 PubMedCrossRefGoogle Scholar
  40. 40.
    Schindl M, Gnant M, Schoppmann SF, Horvat R, Birner P (2007) Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res 27(2):949–952PubMedGoogle Scholar
  41. 41.
    Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J 15(6):593–602. doi: TBJ822[pii]10.1111/j.1524-4741.2009.00822.x PubMedCrossRefGoogle Scholar
  42. 42.
    Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297. doi: S0092867404000455[pii] PubMedCrossRefGoogle Scholar
  43. 43.
    Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135(4):1079–1099. doi: S0016-5085(08)01451-0[pii]10.1053/j.gastro.2008.07.076 PubMedCrossRefGoogle Scholar
  44. 44.
    Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group. J Natl Cancer Inst 101(14):984–992. doi: djp175[pii]10.1093/jnci/djp175 PubMedCrossRefGoogle Scholar
  45. 45.
    Menashe I, Anderson WF, Jatoi I, Rosenberg PS (2009) Underlying causes of the black–white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 101(14):993–1000. doi: djp176[pii]10.1093/jnci/djp176 PubMedCrossRefGoogle Scholar
  46. 46.
    Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, Tsai YC, Williams EH, Lee DH, Stephens RM, Weissman AM, Ambs S (2009) Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One 4(2):e4531. doi: 10.1371/journal.pone.0004531 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Lenora W. M. Loo
    • 1
    • 9
  • Yinghui Wang
    • 2
  • Erin M. Flynn
    • 1
  • Mary Jo Lund
    • 4
    • 8
  • Erin J. Aiello Bowles
    • 5
  • Diana S. M. Buist
    • 5
  • Jonathan M. Liff
    • 4
  • Elaine W. Flagg
    • 6
  • Ralph J. Coates
    • 7
  • J. William Eley
    • 8
  • Li Hsu
    • 2
  • Peggy L. Porter
    • 1
    • 2
    • 3
  1. 1.Division of Human BiologyFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Division of Public Health SciencesFred Hutchinson Cancer Research CenterSeattleUSA
  3. 3.Department of PathologyUniversity of WashingtonSeattleUSA
  4. 4.Department of EpidemiologyRollins School of Public Health, Emory UniversityAtlantaUSA
  5. 5.Group Health Research Institute, Group Health CooperativeSeattleUSA
  6. 6.Division of STD PreventionNational Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and PreventionAtlantaUSA
  7. 7.National Office of Public Health Genomics, Centers for Disease Control and PreventionAtlantaUSA
  8. 8.Hematology and Medical OncologyEmory University School of MedicineAtlantaUSA
  9. 9.Epidemiology ProgramCancer Research Center of Hawaii, University of HawaiiHonoluluUSA

Personalised recommendations